Custom-built models are trained using Revolution Medicines’ proprietary data to discover new drug candidates and receive up to $25 million through advance payments and expected short-term performance-based milestone payments for services related to accessing the industry-leading Neuraxa drug models in revolutionary medicine. Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for cancer patients with RAS addiction, and IAMBIC Therapeutics, a clinical-stage life science and technology company developing clinical-stage life science and technology companies using AI-driven discovery and development platforms, today announced a technology and research collaboration to pursue drug candidates leading the IAI model.
In this multi-year agreement, Iambic will use the structure and molecular library provided by Revolutionary Medicine to train a bespoke version of NeuralPlexer, Iambic’s industry-leading model for prediction of protein ligand structures. Revolution Medicines also has access to the propane model of Iambic, a pre-trained graph neural network deployed in dozens of drug properties for lead selection and optimization.
“We are impressed by the Iambic team and their potential for the platform to enable discovery of new compounds on behalf of the Revolution Medicines portfolio,” said Mark A. Goldsmith, MD, Ph.D., CEO and chairman of Revolution Medicines. “The ability of Iambic’s AI-driven discovery platform, partnering with its own unique collection of data, provides an opportunity to quickly explore oncology goals that are known to be difficult to address through traditional drug discovery approaches.”
Iambic will build custom versions of NeuralPlexer and other technologies trained on proprietary data on revolutionary drugs to inform drug discovery against new drug targets. Both companies have access to improved models, with each company retaining the rights to a limited number of exclusive goals and the ability to specify additional exclusive goals for independent pursuits.
“We’re committed to providing a range of services to our customers,” said Dr. Tom Miller, CEO and co-founder of Iambic. “This collaboration will help us to broaden the impact of AI technology as we strive to build industry-leading models and drugs. We are excited to apply the underlying approaches of this collaboration and provide these approaches externally to great partners like revolutionary drugs.”
Under the agreement, Iambic will receive up to $25 million through a combination of up to payments and expected short-term performance-based milestone payments, along with ongoing research and development reimbursements.
About Iambic’s AI-driven Discovery Platform
The Iambic AI-driven platform was created to address the most challenging design problems of drug discovery, leveraging innovations such as neural plexers for best-in-class prediction of protein and protein ligand structures. Integrating physics principles into the platform’s AI architecture increases data efficiency and allows for wider adventures in the space of chemical structures that allow molecular models to occur. The platform enables identification of new chemical modalities to attract address-dress biological targets, discovering defined product profiles to optimize treatment windows, and multi-parameter optimization for highly distinctive development candidates. By intimately integrating AI-generated molecular design with automated chemical synthesis and experimental execution, Iambic completes the design-make test cycle with a weekly rhythm.
About Iambic Therapeutics
Founded in 2020 and headquartered in San Diego, California, Iambic is disrupting the treatment environment with its proprietary AI-driven drug discovery platform. Iambic has brought together a world-class team with a strong track record of successfully combining pioneering AI experts with experienced drug hunters to provide clinically validated therapeutics. The IAMBIC platform demonstrates the delivery of high-quality, differentiated therapeutics to clinical stages with unprecedented speeds, demonstrating multiple target classes and mechanisms of action. The Iambic team is moving forward with an internal pipeline of clinical assets to meet the needs of urgent, unmet patient. Find out more about the Iambic team, platform, and pipeline at iambic.ai
Iambic Contact Information:
(Email protection)
Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company that develops new targeted therapies for cancer patients with RAS addiction. The company’s R&D pipeline consists of RAS (on) inhibitors designed to suppress a variety of oncogenic variants of RAS proteins. The company’s RAS (on) inhibitors Daraxonrasib (RMC-6236), and Ras (on) multiselective inhibitors. Elironrasib (RMC-6291), RAS(ON) G12C selective inhibitor. Zoldonrasib (RMC-9805) is a RAS (on) G12D selection inhibitor and is currently in clinical development. The company expects RAS (on)G12V selective inhibitor RMC-5127 will become the next RAS (on) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on mutation selection inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
(Email protection)
(Email protection)
Revolutionary Drugs Advance a Positive Statement
This press release contains forward-looking statements relating to revolutionary drugs in the meaning of the US Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be deemed “forward-looking statements.” and the purpose and plan for the collaboration with Iambic Therapeutics. Forward-looking statements are not normally identified by the use of words such as “May,” “will,” “will,” “believe,” “intent,” “plan,” “plan,” “estimate,” and other similar terms that indicate future results. Such forward-looking statements are subject to substantial risks and uncertainties that may make the Company’s development program, future results, performance or results substantially different from the forward-looking statements. These risks and uncertainties include not limited to risks and uncertainties, including the current stage of our program development, the design and implementation process of our previous clinical trials, the design and implementation process of previous clinical trials, and the risk that the results of previous clinical trials do not anticipate the risks associated with challenging future approval processes related to future clinical trials, clinical efficacy, clinical efficacy, or other future nutritional processes. Products are capable of successfully establishing, protecting and defending intellectual property, other matters that may affect the sufficiency of the company’s capital resources, reliance on third parties for manufacturing and development efforts, changing competitive environments, and the impact of global events such as international conflicts and global pandemics on the business of enterprises. For more information on risks and uncertainties that could cause actual results, as well as the results expected in these forward-looking statements, please refer to the Form 10-Q quarterly report filed with the Security and Exchange Committee (“SEC”) on May 7, 2025, and the Form 10-Q filed in the future regular periodic reports. Except as required by law, Revolutionary Pharmaceuticals assume no obligation to update forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unexpected events.
